288 related articles for article (PubMed ID: 29360950)
41. An Observational Cohort Study of
Rao K; Higgins PDR; Young VB
mSphere; 2018; 3(3):. PubMed ID: 29794054
[TBL] [Abstract][Full Text] [Related]
42. A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions.
Nanwa N; Sander B; Krahn M; Daneman N; Lu H; Austin PC; Govindarajan A; Rosella LC; Cadarette SM; Kwong JC
PLoS One; 2017; 12(3):e0172410. PubMed ID: 28257438
[TBL] [Abstract][Full Text] [Related]
43. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
Fukuda H; Yano T; Shimono N
Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364
[TBL] [Abstract][Full Text] [Related]
44. Development and validation of a recurrent Clostridium difficile risk-prediction model.
Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
J Hosp Med; 2014 Jul; 9(7):418-23. PubMed ID: 24700708
[TBL] [Abstract][Full Text] [Related]
45. Analysis of Clostridium difficile infections after cardiac surgery: epidemiologic and economic implications from national data.
Flagg A; Koch CG; Schiltz N; Chandran Pillai A; Gordon SM; Pettersson GB; Soltesz EG
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2404-9. PubMed ID: 24823282
[TBL] [Abstract][Full Text] [Related]
46. Burden of Clostridium difficile on the healthcare system.
Dubberke ER; Olsen MA
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S88-92. PubMed ID: 22752870
[TBL] [Abstract][Full Text] [Related]
47. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.
Razik R; Rumman A; Bahreini Z; McGeer A; Nguyen GC
Am J Gastroenterol; 2016 Aug; 111(8):1141-6. PubMed ID: 27215924
[TBL] [Abstract][Full Text] [Related]
48. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
[TBL] [Abstract][Full Text] [Related]
49. Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians.
Bakken JS; Polgreen PM; Beekmann SE; Riedo FX; Streit JA
Anaerobe; 2013 Dec; 24():20-4. PubMed ID: 24012687
[TBL] [Abstract][Full Text] [Related]
50. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.
Heimann SM; Vehreschild JJ; Cornely OA; Wisplinghoff H; Hallek M; Goldbrunner R; Böttiger BW; Goeser T; Hölscher A; Baldus S; Müller F; Jazmati N; Wingen S; Franke B; Vehreschild MJ
Infection; 2015 Dec; 43(6):707-14. PubMed ID: 26123227
[TBL] [Abstract][Full Text] [Related]
51. Hospital-acquired Clostridium difficile infection: an institutional costing analysis.
Choi KB; Suh KN; Muldoon KA; Roth VR; Forster AJ
J Hosp Infect; 2019 Jun; 102(2):141-147. PubMed ID: 30690051
[TBL] [Abstract][Full Text] [Related]
52. Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective.
Leblanc S; Blein C; Andremont A; Bandinelli PA; Galvain T
Infect Control Hosp Epidemiol; 2017 Aug; 38(8):906-911. PubMed ID: 28756805
[TBL] [Abstract][Full Text] [Related]
53. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study.
Ghosh S; Antunes A; Rinta-Kokko H; Chaparova E; Lay-Flurrie S; Tricotel A; Andersson FL
Int J Infect Dis; 2024 May; 142():106967. PubMed ID: 38368927
[TBL] [Abstract][Full Text] [Related]
54. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).
Wingen-Heimann SM; Davies K; Viprey VF; Davis G; Wilcox MH; Vehreschild MJGT; Lurienne L; Bandinelli PA; Cornely OA; Vilken T; Hopff SM; Vehreschild JJ;
Clin Microbiol Infect; 2023 May; 29(5):651.e1-651.e8. PubMed ID: 36586512
[TBL] [Abstract][Full Text] [Related]
55. Economic Burden of Clostridium difficile Infection in European Countries.
Reigadas Ramírez E; Bouza ES
Adv Exp Med Biol; 2018; 1050():1-12. PubMed ID: 29383660
[TBL] [Abstract][Full Text] [Related]
56. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
Sheitoyan-Pesant C; Abou Chakra CN; Pépin J; Marcil-Héguy A; Nault V; Valiquette L
Clin Infect Dis; 2016 Mar; 62(5):574-580. PubMed ID: 26582748
[TBL] [Abstract][Full Text] [Related]
57. Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
Vitikainen K; Haapamäki J; Färkkilä M; Anttila VJ; Arkkila P
Scand J Gastroenterol; 2018 Aug; 53(8):947-951. PubMed ID: 30041549
[TBL] [Abstract][Full Text] [Related]
58. Burden of Clostridium difficile infection: Associated hospitalization in a cohort of middle-aged and older adults.
Chen Y; Glass K; Liu B; Korda RJ; Riley TV; Kirk MD
Am J Infect Control; 2017 May; 45(5):508-511. PubMed ID: 28089675
[TBL] [Abstract][Full Text] [Related]
59. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
60. Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.
Yu H; Alfred T; Nguyen JL; Zhou J; Olsen MA
Clin Infect Dis; 2023 Feb; 76(3):e1476-e1483. PubMed ID: 35686435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
